6:09 PM
 | 
Nov 12, 2012
 |  BC Extra  |  Clinical News

Idenix gains on CV safety data for IDX184

Idenix Pharmaceuticals Inc. (NASDAQ:IDIX) gained $0.48 (12%) to $4.65 on Monday after reporting that once-daily 50 and 100 mg IDX184 plus pegylated interferon and ribavirin for 12 weeks showed no evidence of severe cardiac findings in a Phase IIb...

Read the full 185 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >